Document Detail

Somatostatin receptor scintigraphy with 111In-DOTA-lanreotide and 111In-DOTA-Tyr3-octreotide in patients with stage IV melanoma: in-vitro and in-vivo results.
MedLine Citation:
PMID:  16314738     Owner:  NLM     Status:  MEDLINE    
The overexpression of somatostatin receptors (SST-Rs) on various tumour cells provides the molecular basis for the successful use of radiolabelled SST analogues in clinical oncology. The objective of the study was to evaluate the tumour binding of In-1,4,7,10-tetraazacyclo-dodecane-N,N',N'',N'''-tetraacetic acid-lanreotide (In-DOTA-LAN) and In-DOTA-tyrosine-octreotide (In-DOTA-Tyr-OCT) in patients with stage IV melanoma. In addition, we evaluated the potential antiproliferative effect of SST analogues, together with an assessment of the functionality of SST-Rs, on four melanoma cell lines. Twenty-three patients with advanced metastatic melanoma underwent scintigraphy. Thirty-eight of 61 lesions (62%) were positively imaged with In-DOTA-LAN, whereas 23 (37%) were negative. With In-DOTA-Tyr-OCT, 10 of the 23 documented lesions (43%) were positive and 13 (56%) were negative. In vitro, cell lines showed no growth inhibition in the presence of SST analogues and no influence on cell cycle distribution was found with the addition of SST analogues to cultured cells. In addition, no functional surface SST-Rs could be demonstrated on these cell lines. Taken together, our results demonstrate the visualization of metastatic melanoma in a high percentage of patients, probably due to binding of SST analogues to SST-Rs on tumour vessels or infiltrating immune cells. Judging from our data, however, there is no evidence of functional SST-R expression on melanoma cells.
Julia Valencak; Elisabeth Heere-Ress; Tatjana Traub-Weidinger; Markus Raderer; Achim Schneeberger; Theresia Thalhammer; Sylvia Aust; Gerhard Hamilton; Irene Virgolini; Hubert Pehamberger
Related Documents :
9595828 - The effect of aqueous extracts from inonotus obliquus on the mitotic index and enzyme a...
11720448 - Drug-induced alterations in tumour perfusion yield increases in tumour cell radiosensit...
12660458 - Testicular sertoli cell tumours and relative sub-types. analysis of clinical and progno...
1032278 - Bioassay of blood-born tumour cells on in vivo and in vitro systems.
1059118 - A model for compartmentation of de novo and salvage thymidine nucleotide pools in mamma...
21461888 - Furanodienone induces cell cycle arrest and apoptosis by suppressing egfr/her2 signalin...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Melanoma research     Volume:  15     ISSN:  0960-8931     ISO Abbreviation:  Melanoma Res.     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2005-11-29     Completed Date:  2006-05-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9109623     Medline TA:  Melanoma Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  523-9     Citation Subset:  IM    
Department of Dermatology, Medical University of Vienna, Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cell Line, Tumor
Heterocyclic Compounds / diagnostic use*,  pharmacokinetics
Indium Radioisotopes / diagnostic use*
Melanoma / metabolism,  pathology,  radionuclide imaging*
Middle Aged
Neoplasm Staging
Octreotide / analogs & derivatives*,  chemistry,  diagnostic use,  pharmacokinetics
Peptides, Cyclic / diagnostic use*,  pharmacokinetics
Radionuclide Imaging / methods
Radiopharmaceuticals / diagnostic use,  pharmacokinetics
Receptors, Somatostatin / metabolism*
Tumor Cells, Cultured
Reg. No./Substance:
0/Heterocyclic Compounds; 0/Indium Radioisotopes; 0/Peptides, Cyclic; 0/Radiopharmaceuticals; 0/Receptors, Somatostatin; 0/indium 111-DOTA-lanreotide; 0/octreotide, DOTA-Tyr(3)-; 83150-76-9/Octreotide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastat...
Next Document:  Isolated melanoma in the lung where there is no known primary site: metastatic disease or primary lu...